Context: Non-functioning Pituitary Adenomas (NFPAs) are fairly common and requires a multidisciplinary approach. There is a lack of reliable markers of a clinical aggressive course. Medical treatment is not available, and transphenoidal surgery is the preferred primary treatment. Objective: We aimed to characterize the somatostatin, estrogen and progesterone receptor distribution for non-functioning pituitary adenomas, and compare it to factors of tumor aggressiveness. Design: Tumor samples for immunohistochemical (N=145) and real time-qPCR (N=106) analyses of SSTR1, SSTR2, SSTR3, SSTR5, Estrogen Receptor α (ERα) and Progesterone Receptor (PR) were measured with immunoreactive score and mRNA relative quantity and retrospectively compared to variables of aggressiveness. Setting: All included patients were operated at the same tertiary referral center. Participants: A total of 164 patients with NFPA where tumor tissue from primary operation was available were included. Results: SSTR3 was expressed abundantly by immunohistochemistry among all NFPAs. The IRS of ERα receptor was correlated to SSTR2 in male patients (p<0.001), but not in female patients (p=0.8). Low ERα receptor level was linked to a higher rate (p=0.001) and earlier reintervention (p=0.004) in male patients, but not in female patients (p=0.95, and p=0.65, respectively). Absence of ERα together with age made a good prediction model for reintervention in male patients with gonadotroph adenomas. Conclusions: SSTR3 is expressed abundantly in NFPAs, hence a possible target for medical treatment. Absence of ERα, together with young age, might serve as a predictor of tumor recurrence in groups of NFPAs. The findings need further validation in systematic prospective studies.
8 April 2021 in Journal of Medical Internet Research
Background: Chronic health conditions are affecting an increasing number of individuals, who experience various symptoms that decrease their quality of life. Digital communication interventions that enable patients to report their symptoms have been shown to positively impact chronic disease management by improving access to care, patient-provider communication, clinical outcomes, and health-related quality of life. These interventions have the potential to prepare patients and health care providers (HCPs) before visits and improve patient-provider communication. Despite the recent rapid development and increasing number of digital communication interventions that have shown positive research results, barriers to realizing the benefits offered through these types of interventions still exist. Objective: The aim of this study is to prepare for the implementation of a digital patient-provider communication intervention in the daily workflow at 2 outpatient clinics by identifying potential determinants of implementation using the Consolidated Framework for Implementation Research (CFIR) to tailor the use of digital communication intervention to the intended context and identify key aspects for an implementation plan. Methods: A combination of focus groups, workshops, and project steering committee meetings was conducted with HCPs (n=14) and patients (n=2) from 2 outpatient clinics at a university hospital. The CFIR was used to guide data collection and analysis. Transcripts, written minutes, and notes were analyzed and coded into 5 CFIR domains using thematic analysis. Results: Data were examined and analyzed into 18 CFIR constructs relevant to the study purpose. On the basis of the identified determinants, important intervention tailoring includes adjustments to the digital features and adjustments to fit the clinical workflow and a decision to conduct a future pilot study. Furthermore, it was decided to provide the intervention to patients as early as possible in their disease trajectory, with tailored information about its use. Key aspects for the implementation plan encompassed maintaining the identified engagement and positive attitude, involving key stakeholders in the implementation process, and providing the needed support and training. Conclusions: This study offers insight into the involvement of stakeholders in the tailoring and implementation planning of a digital communication intervention in clinical practice. Stakeholder involvement in the identification of implementation facilitators and barriers can contribute to the tailoring of digital communication interventions and how they are used and can also inform systematic and targeted implementation planning.
Objective: Reliable biomarkers associated with aggressiveness of non-functioning gonadotroph adenomas (GAs) are lacking. As the growth of tumor remnants is highly variable, molecular markers for growth potential prediction are necessary. We hypothesized that fast- and slow-growing GAs present different gene expression profiles and reliable biomarkers for tumor growth potential could be identified, focusing on the specific role of epithelial-mesenchymal transition (EMT).Design and methods: Eight GAs selected for RNA sequencing were equally divided into fast- and slow-growing group by the tumor volume doubling time (TVDT) median (27.75 months). Data were analyzed by tophat2, cufflinks and cummeRbund pipeline. 40 genes were selected for RT-qPCR validation in 20 GAs based on significance, fold-change and pathway analyses. The effect of silencingMTDH(metadherin) andEMCN(endomucin) onin vitromigration of human adenoma cells was evaluated.Results: 350 genes were significantly differentially expressed (282 genes upregulated and 68 downregulated in the fast group,P-adjusted <0.05). Among 40 selected genes, 11 showed associations with TVDT (−0.669<R<−0.46,P < 0.05). These werePCDH18, UNC5D, EMCN, MYO1B, GPM6Aand six EMT-related genes (SPAG9, SKIL, MTDH, HOOK1, CNOT6LandPRKACB).MTDH, but notEMCN, demonstrated involvement in cell migration and association with EMT markers.Conclusions: Fast- and slow-growing GAs present different gene expression profiles, and genes related to EMT have higher expression in fast-growing tumors. In addition toMTDH, identified as an important contributor to aggressiveness, the other genes might represent markers for tumor growth potential and possible targets for drug therapy.